% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • Archie_Barchie Archie_Barchie Jan 9, 2011 7:22 AM Flag

    flip-flop scientific advisor

    John Kastelein is listed as a scientific advisor for Aegerion on their new website. He once characterized lomitapide as a toxic drug when he was promoting mipomersen for Isis!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Archie, I believe Mipo has been approved for compassionate us for over two years now. So that really isn't an argument as to why AEGR's drug has a better chance than Mipo for FDA approval. t

    • There is an ongoing phase III study for lomitapide listed on that shows the FDA Office of Orphan Drug Development listed as a collaborator. It looks like Aegerion has been working very closely with the FDA on this for a long time. The FDA has already approved lomiapide for compassionate use so they must not be as concerned about lomitapide as they are with mipomersen. Provided that nothing unexpected crops up I'd say they should eventually get approval (if they don't run out of money first).

    • Really Archie, does it make sense that FDA is like almost playing favorites. ISIS is shaking in their boots about whether they have enough data, and good data for the FDA, and Dr. Beer is saying that the FDA is going to let AEGR get by with about 40 times less patients and that FDA even told AEGR that they could simplify their trials. 29 patients in a single armed study, I've never seen that before. It's almost like Dr. Beer's brother-in-law works for the FDA. Would you as an investor looking at this not even have the least bit of trepidation about what was going to transpire? t

    • I can't see how any real scientist would put any validity in a single armed, non-double blinded, placebo controlled phase III study. A one product company that uses an old small molecule drug that calls themselves a "biotech." Time will tell. t

      • 1 Reply to jetmanbash
      • Jetman - You were very busy this weekend over at Isis. I couldn't even follow the thread since it was so long.

        I think this drug has as good a chance a mipomersen but I have my doubts that the market is as big as these Aegerion and Isis are making it.

        Another thing, I saw a Texas TV station that had a story promoting a "new" technique of LDL apheresis. I doubt the apheresis companies are going to let their cash cow lose market share to either Aegerion or Isis without a fight.

1.74+0.05(+2.96%)Aug 24 4:00 PMEDT